As a new active ingredient in Statin group, the first group of drugs for the treatment of dyslipidemia, Pitator has been proven effective with high safety. Launched in Vietnam from mid-2018, Pitator has been provided to major hospitals throughout the country, thereby providing more doctors with treatment options. After a short period of use, Pitator has received positive feedback from medical experts and has been increasingly selected with outstanding advantages.
- Equally effective in reducing LDL-C vs atorvastatin
- Consistently greater increase in HDL-C vs atorvastatin and pravastatin
- Neutral or positive effect on glucose metabolist
- eGFR benefit for patient with CKD
- Preventive effect on CV events
- Well-tolerated with low incidence rate of Aes and DDIs